Metraipolis › archive › dc_ac3e62425d53
Chemotherapy sequential disitamab vedotin in combination with tislelizumab as systemic therapy of upper tract urothelial carcinoma with cutaneous metastasis:… — Europe PMC PMID:41517755
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41517755
- DOI
- 10.1097/md.0000000000046529
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T05:09:57.281Z
- SHA-256 of the archived text
1cecdd09acf7bb7a719aea812d76a3c21df7ead1051afa44ad5a284d5fbaf341- Stable URL of this page
https://metraipolis.com/documento/dc_ac3e62425d53
How to cite
Chemotherapy sequential disitamab vedotin in combination with tislelizumab as systemic therapy of upper tract urothelial carcinoma with cutaneous metastasis:… — Europe PMC PMID:41517755 — Europe PMC (en), https://europepmc.org/article/MED/41517755 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ac3e62425d53 (Metraipolis archive dc_ac3e62425d53, sha256 1cecdd09acf7bb7a719aea812d76a3c21df7ead1051afa44ad5a284d5fbaf341)
BibTeX
@misc{dcac3e62425d53,
title = {Chemotherapy sequential disitamab vedotin in combination with tislelizumab as systemic therapy of upper tract urothelial carcinoma with cutaneous metastasis:… — Europe PMC PMID:41517755},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41517755},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ac3e62425d53; sha256 1cecdd09acf7bb7a719aea812d76a3c21df7ead1051afa44ad5a284d5fbaf341},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41517755. Agents can read the archived copy with the MCP tool read_document.